Financial Summary

BeiGene Ltd.  (BGNE)  $320.71    (%)

  • Symbol
    BGNE
    Price
    320.71$
    Beta
    1.202436
    Volume Avrg.
    440683
    Market Cap
    29590499300
    Last Div
    0
    Range
    118.55-382.2
    Changes
    -37.63
    Changes Percentage
    Exchange
    Nasdaq Global Select
    Industry
    Biotechnology
    Ceo
    Mr. John V. Oyler
    Sector
    Healthcare

About company

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.


Income Statement

Year Revenue Cost of revenues Gross profit Operating expensess Operating incomes Interest expense Income tax expenses Earnings before taxs Net income Earnings per share basics Earnings per share diluteds Dividend per shares Gross margins EBIT margins Profit margins EBITDA EBIT Earnings Before Tax Margins Net Profit Margins
2020 274515.00 169559.00 104956.00 38668.00 66288.00 0.00 968.00 67091.00 57411.00 3.31 3.28 0.803333414346 0.382332477278109 0.300289471658 0.209136112780722 77344.00 66288.00 0.244398302460703 0.209136112780722
2019 260174.00 161782.00 98392.00 34462.00 6393.00 3576.00 10481.00 65737.00 55256.00 2.97145 2.97145 3.03705403822 0.378178 0.245720171885 0.212381 8186.00 6393.00 0.252666 0.212381
2018 265595.00 163756.00 101839.00 30941.00 70898.00 324.00 11872.00 72903.00 59531.00 2.97649 2.97649 2.74234021698 0.383437 0.266940266195 0.224142 85546.00 70898.00 0.274489 0.224142
2017 229234.00 141048.00 88186.00 26842.00 61344.00 2323.00 15738.00 64089.00 48351.00 2.3175 2.3025 2.43140686849 0.384698604918991 0.267604282087 0.210924208450753 76569.00 61344.00 0.27957894553164 0.210924208450753
2016 215639.00 131376.00 84263.00 24239.00 60024.00 1456.00 15685.00 61372.00 45687.00 2.07658 2.07658 2.20897805039 0.39076 0.278354101067 0.211868 73333.00 60024.00 0.284605 0.211868
2015 233715.00 140089.00 93626.00 22396.00 7123.00 733.00 19121.00 72515.00 53394.00 2.30422 2.30422 1.99566067658 0.400599 0.304772907173 0.228458 84505.00 7123.00 0.310271 0.228458
2014 182795.00 112258.00 70537.00 18034.00 52503.00 384.00 13973.00 53483.00 3951.00 1.61318 1.61318 1.817183144 0.38588 0.287223392325 0.216144 61813.00 52503.00 0.292585 0.216144
2013 17091.00 106606.00 64304.00 15305.00 48999.00 136.00 13118.00 50155.00 37037.00 1.41969 1.41969 11.338876116 0.376245 0.286694751624 0.216705 57048.00 48999.00 0.293459 0.216705
2012 156508.00 87846.00 68662.00 13421.00 55241.00 1088.00 1403.00 55763.00 41733.00 1.57673 1.57673 2.63181556135 0.438712 0.35295959312 0.266651 60128.00 55241.00 0.356295 0.266651
2011 108249.00 64431.00 43818.00 10028.00 3379.00 519.00 8283.00 34205.00 25922.00 0.98833 0.98833 0.0 0.404789 0.312150689614 0.239466 36538.00 3379.00 0.315984 0.239466
2010 65225.00 39541.00 25684.00 7299.00 18385.00 311.00 4527.00 1854.00 14013.00 0.54121 0.54121 0.0 0.393775 0.281870448448 0.214841 19878.00 18385.00 0.284247 0.214841
2009 42905.00 25683.00 17222.00 5482.00 1174.00 407.00 3831.00 12066.00 8235.00 0.32426 0.32426 0.0 0.401398 0.2812 0.191936 13207.00 12066.00 0.281226 0.191936
Year202020192018201720162015201420132012201120102009
Revenue274515.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues169559.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense0.003576.00324.002323.001456.00733.00384.00136.001088.00519.00311.00407.00
Income tax expenses968.0010481.0011872.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.312.971452.976492.31752.076582.304221.613181.419691.576730.988330.541210.32426
Earnings per share diluteds3.282.971452.976492.30252.076582.304221.613181.419691.576730.988330.541210.32426
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.008186.0085546.0076569.0073333.0084505.0061813.0057048.0060128.0036538.0019878.0013207.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.240.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.210.220.210.210.230.220.220.270.240.210.19